Approach to adenovirus infections in the setting of hematopoietic cell transplantation

Current Opinion in Infectious Diseases

Volumn 30, Issue 4, 2017, Pages 377-387

  Lee, Yeon Joo ^a   Prockop, Susan E ^a   Papanicolaou, Genovefa A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

adenovirus; adoptive cell therapy allogenic hematopoietic cell transplantation; brincidofovir

Indexed keywords

BIOLOGICAL PRODUCT; BRINCIDOFOVIR; CIDOFOVIR;

ADENOVIRUS INFECTION; ADOPTIVE TRANSFER; ANTIVIRAL THERAPY; BIOLOGICAL THERAPY; CYTOTOXIC T LYMPHOCYTE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT MONITORING; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVIEW; SEROTYPE; SYMPTOM; VIRUS DETECTION; VIRUS LOAD; ADENOVIRIDAE; VIROLOGY;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 85021697113     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000379     Document Type: Review

References (92)

1. Lee YJ, Huang YT, Kim SJ, et al. Adenovirus viremia in adult CD34+ selected hematopoietic cell transplant recipients: low incidence and high clinical impact. Biol Blood Marrow Transplant 2016; 22:174-178.
2. Sive JI, Thomson KJ, Morris EC, et al. Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Clin Infect Dis 2012; 55:1362-1370.
3. Ohrmalm L, Lindblom A, Omar H, et al. Evaluation of a surveillance strategy for early detection of adenovirus by PCR of peripheral blood in hematopoietic SCT recipients: incidence and outcome. Bone Marrow Transplant 2011; 46:267-272.
4. Rustia E, Violago L, Jin Z, et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22:1646-1653.
5. Hiwarkar P, Gaspar HB, Gilmour K, et al. Impact of viral reactivations in the era of preemptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013; 48:803-808.
6. Mynarek M, Ganzenmueller T, Mueller-Heine A, et al. Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program. Biol Blood Marrow Transplant 2014; 20:250-256.
7. Schilham MW, Claas EC, van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002; 35:526-532.
8. Ganzenmueller T, Buchholz S, Harste G, et al. High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load. J Clin Virol 2011; 52:55-59.
9. Lee YJ, Chung D, Xiao K, et al. Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution. Biol Blood Marrow Transplant 2013; 19:387-392.
10. Prasad VK, Papanicolaou GA, Marón GM, et al. Treatment of adenovirus (AdV) infection in allogeneic hematopoietic cell transplant (allo HCT) patients (pts) with brincidofovir: final 36 week results from the ADVise trial. Biol Blood Marrow Transplant 2017; 23:S57-S58.
11. Rowe WP, Huebner RJ, Gilmore LK, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953; 84:570-573.
12. Gahery-Segard H, Farace F, Godfrin D, et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and antipenton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72:2388-2397.
13. Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev 2014; 27:441-462.
14. Lynch JP 3rd, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med 2016; 37:586-602.
15. Lenaerts L, De Clercq E, Naesens L. Clinical features and treatment of adenovirus infections. Rev Med Virol 2008; 18:357-374.
16. Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infectious Dis Rep 2014; 16:416.
17. Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Brit J Haematol 2005; 128:503-509.
18. Tang J, Olive M, Pulmanausahakul R, et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virol 2006; 350:312-322.
19. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76:10608-10616.
20. Adrian T, Schafer G, Cooney MK, et al. Persistent enteral infections with adenovirus types 1 and 2 in infants: no evidence of reinfection. Epidemiol Infect 1988; 101:503-509.
21. Veltrop-Duits LA, van Vreeswijk T, Heemskerk B, et al. High titers of preexisting adenovirus serotype-specific neutralizing antibodies in the host predict viral reactivation after allogeneic stem cell transplantation in children. Clin Infect Dis 2011; 52:1405-1413.
22. Feghoul L, Chevret S, Cuinet A, et al. Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral preemptive treatment. Clin Microbiol Infect 2015; 21:701-709.
23. Lion T, Kosulin K, Landlinger C, et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 2010; 24:706-714.
24. de Pagter AP, Haveman LM, Schuurman R, et al. Adenovirus DNA positivity in nasopharyngeal aspirate preceding hematopoietic stemcell transplantation: a very strong risk factor for adenovirus DNAemia in pediatric patients. Clin Infect Dis 2009; 49:1536-1539.
25. Nakazawa Y, Saito S, Yanagisawa R, et al. Recipient seropositivity for adenovirus type 11 (AdV11) is a highly predictive factor for the development of AdV11-induced hemorrhagic cystitis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48:737-739.
26. Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116:5476-5485.
27. Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 2012; 14:555-563.
28. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143-1238.
29. Yilmaz M, Chemaly RF, Han XY, et al. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 2013; 48:1218-1223.
30. Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191:520-530.
31. Taniguchi K, Yoshihara S, Tamaki H, et al. Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. Ann Hematol 2012; 91:1305-1312.
32. Schonberger S, Meisel R, Adams O, et al. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:1428-1435.
33. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008; 21:704-715.
34. Bae A, Sethna P, Brundage TM, et al. Role of adenovirus species and type on virologic response to brincidofovir. Biol Blood Marrow Transplant 2016; 22:S55.
35. Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:1333-1338.
36. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Brit J Haematol 2005; 130:595-603.
37. Gray GC, McCarthy T, Lebeck MG, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis 2007; 45:1120-1131.
38. Lugthart G, Oomen MA, Jol-van der Zijde CM, et al. The effect of cidofovir on adenovirus plasma DNA levels in stemcell transplantation recipients without T cell reconstitution. Biol Blood Marrow Transplant 2015; 21:293-299.
39. Kroes AC, de Klerk EP, Lankester AC, et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol 2007; 38:341-347.
40. Williams KM, Agwu AL, Dabb AA, et al. A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol 2009; 31:825-831.
41. Hiwarkar P, Amrolia P, Sivaprakasam P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood 2017; 129:2033.
42. Ganapathi L, Arnold A, Jones S, et al. Use of cidofovir in pediatric patients with adenovirus infection. F1000Res 2016; 5:758; Callan et al. [42]
43. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12:219-227.
44. Matthes-Martin S, Boztug H, Lion T. Diagnosis and treatment of adenovirus infection in immunocompromised patients. Expert Rev Anti Infect Ther 2013; 11:1017-1028.
45. Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012; 18:731-738.
46. Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transplant 2017; 23:512-521.
47. Saliba RM, Rezvani K, Leen A, et al. General and virus-specific immune cell reconstitution after double cord blood transplantation. Biol Blood Marrow Transplant 2015; 21:1284-1290.
48. Schultze-Florey RE, Tischer S, Schwerk N, et al. Monitoring of adenovirus (ADV)-specific T cells in a boy with ADV pneumonia and disseminated disease after lung transplantation. Transpl Infect Dis 2016; 18:756-760.
49. van Montfrans J, Schulz L, Versluys B, et al. Viral PCR positivity in stool before allogeneic hematopoietic cell transplantation is strongly associated with acute intestinal graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21:772-774.
50. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10:186-194.
51. Morfin F, Dupuis-Girod S, Frobert E, et al. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone. Antivir Ther 2009; 14:55-61.
52. Chen FE, Liang RH, Lo JY, et al. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant 1997; 20:997-999.
53. Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521-1525.
54. Kaneko H, Mori S, Suzuki O, et al. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res 2004; 61:63-66.
55. Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 2000; 41:460-463.
56. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388-394.
57. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-486.
58. Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005; 19:455-462.
59. Bhadri VA, Lee-Horn L, Shaw PJ. Safety and tolerability of cidofovir in high-risk pediatric patients. Transpl Infect Dis 2009; 11:373-379.
60. MullerWJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41:1812-1816.
61. Tippin TK, Morrison ME, Brundage TM, Mommeja-Marin H. Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther Drug Monit 2016; 38:777-786.
62. Paolino K, Sande J, Perez E, et al. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol 2011; 50:167-170.
63. Voigt S, Hofmann J, Edelmann A, et al. Brincidofovir clearance of acyclovirresistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. Transpl Infect Dis 2016; 18:791-794.
64. Camargo JF, Morris MI, Abbo LM, et al. The use of brincidofovir for the treatment of mixed dsDNA viral infection. J Clin Virol 2016; 83:1-4.
65. Tippin TS, Savina P, Van Sickle V, Naderer O. Tissue Distribution of Radioactivity after Intravenous and Oral Administration of [14C]Brincidofovir to Rats. Denver, CO: AAPS; 2016. Available from: http://abstracts.aaps.org/Verify/ AAPS2016/PosterSubmissions/18W0200.pdf.
66. Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998; 187:1395-1402.
67. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619-1627.
68. Schultze-Florey RE, Tischer S, Kuhnau W, et al. Persistent recipient-derived human adenovirus (HAdV)-specific T cells promote HAdV control after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2017; 52:609-611.
69. Watson T, MacDonald D, Song X, et al. Risk factors for molecular detection of adenovirus in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2012; 18:1227-1234.
70. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-241.
71. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-1191.
72. Hromas R, Cornetta K, Srour E, et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84:1689-1690.
73. Leen AM, Sili U, Savoldo B, et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004; 103:1011-1019.
74. Comoli P, Schilham MW, Basso S, et al. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother 2008; 31:529-536.
75. Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirusspecific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012; 20:1622-1632.
76. Horlock C, Skulte A, Mitra A, et al. Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of posttransplant infectious complications. Cytotherapy 2016; 18:1209-1218.
77. Geyeregger R, Freimuller C, Stemberger J, et al. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother 2014; 37:245-249.
78. Di Nardo M, Li PiraG, Amodeo A, et al. Adoptive immunotherapy with antigenspecific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation. Pediatr Blood Cancer 2014; 61:376-379.
79. Feuchtinger T, Lang P, Hamprecht K, et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32:282-289.
80. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Brit J Haematol 2007; 136:117-126.
81. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virusspecific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Brit J Haematol 2006; 134:64-76.
82. Chakupurakal G, Onion D, Bonney S, et al. HLA-peptide multimer selection of adenovirus-specific T cells for adoptive T-cell therapy. J Immunother 2013; 36:423-431.
83. Uhlin M, Gertow J, Uzunel M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012; 55:1064-1073.
84. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114:4283-4292.
85. Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125:1986-1994.
86. Qasim W, Gilmour K, Zhan H, et al. Interferon-gamma capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. Brit J Haematol 2013; 161:449-452.
87. Naik S, Nicholas SK, Martinez CA, et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 2016; 137:1498-1505.
88. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6:242ra83.
89. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked thirdparty virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121:5113-5123.
90. Tischer S, Geyeregger R, Kwoczek J, et al. Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection. J Transl Med 2016; 14:286.
91. Schaar K, Roger C, Pozzuto T, et al. Biological antivirals for treatment of adenovirus infections. Antivir Ther 2016; 21:559-566.
92. Pozzuto T, Roger C, Kurreck J, Fechner H. Enhanced suppression of adenovirus replication by triple combination of antiadenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir. Antiviral Res 2015; 120:72-78.